JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-793-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the USA), or (+1) 781-489-7301 www.bccresearch.com information@bccresearch.com
TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2 STUDY OBJECTIVES 2 REASONS FOR DOING THIS STUDY 2 CONTRIBUTIONS OF THE STUDY AND FOR WHOM 3 SCOPE OF THE STUDY 3 METHODOLOGY 3 INFORMATION SOURCES 3 ABOUT THE AUTHOR 4 RELATED BCC RESEARCH REPORTS 4 BCC RESEARCH WEBSITE 5 DISCLAIMER 5 CHAPTER 2 EXECUTIVE SUMMARY 7 SUMMARY TABLE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018 ($ MILLIONS) SUMMARY FIGURE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018) ($ MILLIONS) 8 8 CHAPTER 3 OVERVIEW 11 JANUS KINASE (JAK) AND PHOSPHOINOSITIDE 3-KINASES (PI3K) 11 SIGNAL TRANSDUCTION THERAPIES/INHIBITORS FOR JAK AND PI3K 11 MECHANISM OF ACTION 12 Janus Kinase Therapies/Inhibitors 12 Phosphoinositide 3-kinases (PI3K) Therapies/Inhibitors 12 APPROVED HISTONE DEACETYLASE INHIBITORS 12 CLASSIFICATION 13 JANUS KINASE (JAK) 13 TABLE 1 CLASSIFICATION OF JANUS KINASE (JAK) 13 PHOSPHOINOSITIDE 3-KINASES (PI3K) 13 TABLE 2 CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES (PI3K) 14 JANUS KINASE THERAPIES/INHIBITORS 14 Ruxolitinib (INC424/INCB18424) 15 FIGURE 1 STRUCTURE OF INC424 (RUXOLITINIB) 15 Tofacitinib (CP-690,550) 15 FIGURE 2 STRUCTURE OF CP-690,550 (TOFACITINIB) 16 Baricitinib (INC28050/LY3009104) 16 FIGURE 3 STRUCTURE OF BARICITINIB (INC28050/LY3009104) 16 NS-018 17 Momelotinib (CYT-387) 17 FIGURE 4 STRUCTURE OF MOMELOTINIB (CYT-387) 17 AT9283 18 FIGURE 5 STRUCTURE OF AT9283 18 Pacritinib (SB1518) 18 FIGURE 6 STRUCTURE OF PACRITINIB (SB1518) 18 LY2784544 19 FIGURE 7 STRUCTURE OF LY2784544 19
TG101348 (SAR302503) 19 FIGURE 8 STRUCTURE OF TG101348 (SAR302503) 19 BMS911543 20 FIGURE 9 STRUCTURE OF BMS911543 20 Lestaurtinib (CEP-701) 20 FIGURE 10 STRUCTURE OF LESTAURTINIB (CEP-701) 20 LS104 21 WP1066 21 FIGURE 11 STRUCTURE OF WP1066 21 AG490 22 FIGURE 12 STRUCTURE OF AG490 22 AZD1480 22 FIGURE 13 STRUCTURE OF AZD1480 23 INCB39110 23 INCB47986 23 PHOSPHOINOSITIDE 3-KINASES (PI3K) THERAPIES/INHIBITORS 23 Wortmannin 24 FIGURE 14 STRUCTURE OF WORTMANNIN 24 Perifosine (KRX-0401) 25 FIGURE 15 STRUCTURE OF PERIFOSINE (KRX-0401) 25 LY294002 25 FIGURE 16 STRUCTURE OF LY294002 26 Idelalisib (GS-1101, CAL-101) 26 FIGURE 17 STRUCTURE OF IDELALISIB (GS-1101, CAL-101) 26 PX-866 27 FIGURE 18 STRUCTURE OF PX-866 27 IPI-145 27 FIGURE 19 STRUCTURE OF IPI-145 27 BKM120 28 FIGURE 20 STRUCTURE OF BKM120 28 Copanlisib (BAY80-6946) 29 FIGURE 21 STRUCTURE OF COPANLISIB (BAY 80-6946) 29 PF-05212384 (PKI-587) 29 FIGURE 22 STRUCTURE OF PF-05212384 (PKI-587) 30 Pictilisib (GDC-0941) 30 FIGURE 23 STRUCTURE OF PICTILISIB (GDC-0941) 30 Dactolisib (BEZ235) 31 FIGURE 24 STRUCTURE OF DACTOLISIB (BEZ235) 31 Apitolisib (GDC-0980) 31 FIGURE 25 STRUCTURE OF APITOLISIB (GDC-0980) 31 ZSTK474 32 FIGURE 26 STRUCTURE OF ZSTK474 32 SAR245409 (XL765) 32 FIGURE 27 STRUCTURE OF SAR245409 (XL765) 33 SAR245408 (XL147) 33 FIGURE 28 STRUCTURE OF APITOLISIB SAR245408 (XL147) 33 BYL719 34
FIGURE 29 STRUCTURE OF APITOLISIB BYL719 34 SIGNAL TRANSDUCTION BIOMARKERS FOR JAK AND PI3K 34 PROSPECTIVE DISEASE TARGETS FOR JAK AND PI3K THERAPIES 35 TABLE 3 SIGNAL TRANSDUCTION THERAPIES/INHIBITORS - PROSPECTIVE DISEASE TARGETS 36 CHAPTER 4 REGULATORY ASPECTS 42 RUXOLITINIB (INC424) 43 DOSING INFORMATION 43 Dose Modifications 43 SAFETY INFORMATION 43 Safety of Ruxolitinib in Specific Population 44 RISK OF INFECTION 45 Tuberculosis 45 Progressive Multifocal Leukoencephalopathy (PML) 45 Herpes Zoster 45 TOFACITINIB (CP-690,550) 45 DOSING INFORMATION 45 Dose Modifications 45 SAFETY INFORMATION 46 Safety of Tofacitinib in Specific Populations 46 RISK OF INFECTION 47 Tuberculosis 47 REGULATORY DEVELOPMENTS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS 47 CHAPTER 5 NEW DEVELOPMENTS 50 NEW DEVELOPMENTS 50 TABLE 4 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT TABLE 5 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) IN COMBINATION WITH OTHER AGENTS TABLE 6 NUMBER OF ONGOING TRIALS FOR MAJOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT AND COMBINATION THERAPY COLLABORATIVE TRIALS AND FUTURE ACTIVITIES 67 51 57 66 CHAPTER 6 MARKET ANALYSIS-SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) 70 MARKET BY THE TYPE 71 TABLE 7 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, THROUGH 2018 ($ MILLIONS) FIGURE 30 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2011-2018 RUXOLITINIB (INC424, INCB18424)-JANUS KINASE (JAK) INHIBITOR 72 Market Overview 72 Market Revenue 73 TABLE 8 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, THROUGH 2018 ($ MILLIONS) FIGURE 31 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, 2011-2018 ($ MILLIONS) 71 71 74 74
TOFACITINIB (CP-690,550)-JANUS KINASE (JAK) INHIBITOR 74 Market Overview 75 Market Revenue 75 TABLE 9 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, THROUGH 2018 ($ MILLIONS) FIGURE 32 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, 2011-2018 ($ MILLIONS) MARKET SHARE 77 TABLE 10 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%) FIGURE 33 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%) MARKET BY REGION 77 MARKET OVERVIEW 78 MARKET REVENUE 79 TABLE 11 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, THROUGH 2018 ($ MILLIONS) FIGURE 34 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2011-2018 ($ MILLIONS) MARKET SHARE 80 TABLE 12 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS) FIGURE 35 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS) PROSPECTIVE FUTURE MARKET FOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) INDUSTRY STRUCTURE 81 MARKET LEADERS 82 TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS MARKET SHARES 83 TABLE 14 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%) FIGURE 36 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%) MARKET APPLICATIONS 84 TABLE 15 APPLICATION AREAS OF COMBINATION THERAPY OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (FOR JAK AND PI3K) WITH OTHER THERAPIES MYELOFIBROSIS 86 RHEUMATOID ARTHRITIS 86 MARKET OVERVIEW 87 MARKET REVENUE 89 TABLE 16 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, THROUGH 2018 ($ MILLIONS) FIGURE 37 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, 2011-2018 ($ MILLIONS) MARKET SHARE 90 76 76 77 77 79 79 80 80 81 82 83 84 85 89 89
TABLE 17 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%) FIGURE 38 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%) PROSPECTIVE APPLICATION OF SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) CANCER 91 INFLAMMATORY DISEASES 92 CARDIAC AILMENTS 92 OTHERS 93 90 90 91 CHAPTER 7 PATENT ANALYSIS 95 PATENTS BY YEAR 96 TABLE 18 TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013 96 FIGURE 39 TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013 96 PATENTS BY SIGNAL TRANSDUCTION THERAPIES CATEGORY (JAK AND PI3K) 96 TABLE 19 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, 2011-2013 FIGURE 40 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, 2011-2013 PATENTS BY SIGNAL TRANSDUCTION THERAPIES TYPE 97 PATENTS BY JANUS KINASE (JAK) BASED THERAPIES/ INHIBITORS/BIOMARKERS TABLE 20 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED FIGURE 41 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/ INHIBITORS/BIOMARKERS, 2011-2013 PATENTS BY PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS TABLE 21 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED FIGURE 42 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED PATENTS BY COUNTRY 99 JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS 99 TABLE 22 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED FIGURE 43 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED TABLE 23 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED (%) FIGURE 44 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED (%) PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/ INHIBITORS/BIOMARKERS TABLE 24 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED FIGURE 45 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED TABLE 25 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED (%) 97 97 97 98 98 98 99 99 100 100 101 101 102 102 102 103
FIGURE 46 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED (%) PATENTS BY COMPANY 103 JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS 103 TABLE 26 NUMBER OF U.S. PATENTS BY COMPANY FOR JANUS KINASE (JAK) BASED PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/ INHIBITORS/BIOMARKERS TABLE 27 NUMBER OF U.S. PATENTS BY COMPANY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED PATENTS BY ASSIGNEE 106 JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS 106 TABLE 28 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED FIGURE 47 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS TABLE 29 PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED FIGURE 48 PATENTS BY ASSGINEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED 103 104 105 105 106 106 107 107 107 CHAPTER 8 CURRENT SITUATION 110 NEW TECHNOLOGIES AND PLATFORMS IN SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) SCREENING TECHNOLOGY 111 PYRAMID 111 BIOMARKERS 111 FACTORS AFFECTING THE SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET CURRENT DRIVERS OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET COLLABORATIONS/ACQUISITIONS 113 TABLE 30 FUNDINGS IN SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) 111 112 112 113 CHAPTER 9 COMPANY PROFILES 117 ABBVIE INC. 117 AETERNA ZENTARIS INC. 117 AMGEN INC 119 ASTELLAS PHARMA INC. 119 ASTEX PHARMACEUTICALS INC 120 ASTRAZENECA PLC 121 BAYER HEALTHCARE PHARMACEUTICALS 121 CELL THERAPEUTICS INC 122 CURIS INC. 124 DAIICHI SANKYO CO. LTD 124 ELI LILLY AND CO. 125 EXELIXIS INC. 126
GALAPAGOS NV 126 GENENTECH INC 128 GILEAD SCIENCES INC. 128 GLAXOSMITHKLINE 129 INCYTE CORP. 130 INFINITY PHARMACEUTICALS INC. 132 ITALFARMACO S.P.A. 133 JANSSEN BIOTECH INC. 134 MEI PHARMA INC. 134 MERCK & CO. INC. 135 MILLENNIUM 135 NATIONAL CANCER INSTITUTE 136 NIPPON ZENYAKU KOGYO CO., LTD. 137 NOVARTIS INTERNATIONAL AG 138 NS PHARMA, INC 139 ONCOTHYREON INC 139 PATHWAY THERAPEUTICS LTD 140 PFIZER 141 PIRAMAL ENTERPRISES LIMITED 142 PORTOLA PHARMACEUTICALS INC 142 RIGEL PHARMACEUTICALS INC. 143 SANOFI ONCOLOGY 144 TEVA PHARMACEUTICALS INDUSTRIES LTD 145 TG THERAPEUTICS INC. 146 VERASTEM INC. 146 VERTEX PHARMACEUTICALS INC 147 WILEX AG 148 XCOVERY HOLDING COMPANY, LLC 148 CHAPTER 10 APPENDIX I-ABBREVIATIONS 151
LIST OF TABLES TABLE HEADING SUMMARY TABLE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018 ($ MILLIONS) TABLE 1 CLASSIFICATION OF JANUS KINASE (JAK) 13 TABLE 2 CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES (PI3K) 14 TABLE 3 SIGNAL TRANSDUCTION THERAPIES/INHIBITORS - PROSPECTIVE DISEASE TARGETS TABLE 4 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT TABLE 5 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) IN COMBINATION WITH OTHER AGENTS TABLE 6 NUMBER OF ONGOING TRIALS FOR MAJOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT AND COMBINATION THERAPY TABLE 7 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, THROUGH 2018 ($ MILLIONS) TABLE 8 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, THROUGH 2018 ($ MILLIONS) TABLE 9 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, THROUGH 2018 ($ MILLIONS) TABLE 10 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%) TABLE 11 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, THROUGH 2018 ($ MILLIONS) TABLE 12 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS) TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS TABLE 14 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%) TABLE 15 APPLICATION AREAS OF COMBINATION THERAPY OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (FOR JAK AND PI3K) WITH OTHER THERAPIES TABLE 16 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, THROUGH 2018 ($ MILLIONS) TABLE 17 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%) TABLE 18 TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013 96 TABLE 19 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, 2011-2013 TABLE 20 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED TABLE 21 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED TABLE 22 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED TABLE 23 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED (%) TABLE 24 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED TABLE 25 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED (%) 8 36 51 57 66 71 74 76 77 79 80 82 83 85 89 90 97 98 99 100 101 102 103
TABLE HEADING TABLE 26 NUMBER OF U.S. PATENTS BY COMPANY FOR JANUS KINASE (JAK) BASED TABLE 27 NUMBER OF U.S. PATENTS BY COMPANY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED TABLE 28 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED TABLE 29 PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED TABLE 30 FUNDINGS IN SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) 104 105 106 107 113
LIST OF FIGURES FIGURE TITLE SUMMARY FIGURE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018) ($ MILLIONS) FIGURE 1 STRUCTURE OF INC424 (RUXOLITINIB) 15 FIGURE 2 STRUCTURE OF CP-690,550 (TOFACITINIB) 16 FIGURE 3 STRUCTURE OF BARICITINIB (INC28050/LY3009104) 16 FIGURE 4 STRUCTURE OF MOMELOTINIB (CYT-387) 17 FIGURE 5 STRUCTURE OF AT9283 18 FIGURE 6 STRUCTURE OF PACRITINIB (SB1518) 18 FIGURE 7 STRUCTURE OF LY2784544 19 FIGURE 8 STRUCTURE OF TG101348 (SAR302503) 19 FIGURE 9 STRUCTURE OF BMS911543 20 FIGURE 10 STRUCTURE OF LESTAURTINIB (CEP-701) 20 FIGURE 11 STRUCTURE OF WP1066 21 FIGURE 12 STRUCTURE OF AG490 22 FIGURE 13 STRUCTURE OF AZD1480 23 FIGURE 14 STRUCTURE OF WORTMANNIN 24 FIGURE 15 STRUCTURE OF PERIFOSINE (KRX-0401) 25 FIGURE 16 STRUCTURE OF LY294002 26 FIGURE 17 STRUCTURE OF IDELALISIB (GS-1101, CAL-101) 26 FIGURE 18 STRUCTURE OF PX-866 27 FIGURE 19 STRUCTURE OF IPI-145 27 FIGURE 20 STRUCTURE OF BKM120 28 FIGURE 21 STRUCTURE OF COPANLISIB (BAY 80-6946) 29 FIGURE 22 STRUCTURE OF PF-05212384 (PKI-587) 30 FIGURE 23 STRUCTURE OF PICTILISIB (GDC-0941) 30 FIGURE 24 STRUCTURE OF DACTOLISIB (BEZ235) 31 FIGURE 25 STRUCTURE OF APITOLISIB (GDC-0980) 31 FIGURE 26 STRUCTURE OF ZSTK474 32 FIGURE 27 STRUCTURE OF SAR245409 (XL765) 33 FIGURE 28 STRUCTURE OF APITOLISIB SAR245408 (XL147) 33 FIGURE 29 STRUCTURE OF APITOLISIB BYL719 34 FIGURE 30 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2011-2018 FIGURE 31 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, 2011-2018 ($ MILLIONS) FIGURE 32 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, 2011-2018 ($ MILLIONS) FIGURE 33 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%) FIGURE 34 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2011-2018 ($ MILLIONS) FIGURE 35 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS) FIGURE 36 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%) FIGURE 37 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, 2011-2018 ($ MILLIONS) 8 71 74 76 77 79 80 84 89
FIGURE TITLE FIGURE 38 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%) FIGURE 39 TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013 96 FIGURE 40 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, 2011-2013 FIGURE 41 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/ INHIBITORS/BIOMARKERS, 2011-2013 FIGURE 42 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED FIGURE 43 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED FIGURE 44 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED (%) FIGURE 45 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED FIGURE 46 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED (%) FIGURE 47 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED FIGURE 48 PATENTS BY ASSGINEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED 90 97 98 99 100 101 102 103 106 107